Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Non-Small-Cell Lung 53Lung Neoplasms 24Breast Neoplasms 22Head and Neck Neoplasms 14Adenocarcinoma of Lung 11Neoplasms 7Esophageal Neoplasms 7Brain Neoplasms 7Prostatic Neoplasms 6Adenocarcinoma, Bronchiolo-Alveolar 6Neoplasm Metastasis 5Glioblastoma 5Adenocarcinoma Of Esophagus 5Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Ovarian Neoplasms 4Gliosarcoma 4Colorectal Neoplasms 4Colonic Neoplasms 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Skin Neoplasms 2Neoplasms, Squamous Cell 2Mesothelioma, Malignant 2Lymphoid Interstitial Pneumonia 2Laryngeal Diseases 2

Interventions

pembrolizumab 4Docetaxel 3Cisplatin 3Cetuximab 3Gefitinib 2Cyclophosphamide 2zalutumumab 1fludarabine phosphate 1fludarabine 1durvalumab 1atezolizumab 1advexin 1abemaciclib 1Vorinostat 1Radiotherapy 1Radiosurgery 1Oxaliplatin 1Nivolumab 1Imatinib Mesylate 1Everolimus 1Erlotinib Hydrochloride 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Squamous Cell × Gefitinib × Clear all
NCT00229723 2009-08-04

IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

AstraZeneca

Phase 2 Completed
224 enrolled 21 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms, Squamous Cell

NCT00255476 2009-04-23

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

AstraZeneca

Phase 2 Completed
64 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡